0001209191-18-024453.txt : 20180409 0001209191-18-024453.hdr.sgml : 20180409 20180409202259 ACCESSION NUMBER: 0001209191-18-024453 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180405 FILED AS OF DATE: 20180409 DATE AS OF CHANGE: 20180409 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hora Maninder CENTRAL INDEX KEY: 0001443159 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24006 FILM NUMBER: 18746674 MAIL ADDRESS: STREET 1: PDL BIOPHARMA, INC. STREET 2: 1400 SEAPORT BOULEVARD CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 4154825300 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-04-05 0 0000906709 NEKTAR THERAPEUTICS NKTR 0001443159 Hora Maninder C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 0 1 0 0 SVP Pharma Dev & Mfg Ops Common Stock 2018-04-05 4 M 0 20000 7.21 A 100261 D Common Stock 2018-04-05 4 S 0 20000 101.75 D 80261 D Common Stock 2018-04-09 4 M 0 9498 7.21 A 89759 D Common Stock 2018-04-09 4 S 0 9498 105.05 D 80261 D Stock Option 7.21 2018-04-05 4 M 0 20000 0.00 D 2016-02-08 2020-02-07 Common Stock 20000 42500 D Stock Option 7.21 2018-04-09 4 M 0 9498 0.00 D 2016-02-08 2020-02-07 Common Stock 9498 33002 D This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This number includes 6,500 shares held by the reporting person from the Issuer's ESPP plan. The acquisition of these shares under this plan is exempt under Rule 16b-3(c). This transaction was executed in multiple trades at prices ranging from $100.26 - $103.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. This transaction was executed in multiple trades at prices ranging from $105.00 - $105.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Mark A. Wilson, Attorney-in-Fact 2018-04-09